Advanced search
1 file | 1.36 MB Add to list

Imaging modalities in synchronous oligometastatic prostate cancer

(2019) WORLD JOURNAL OF UROLOGY. 37(12). p.2573-2583
Author
Organization
Abstract
Purpose Along with a number of other malignancies, the term "oligometastatic" prostate cancer has recently emerged. It represents an attempt to define a subtype of cancer with a limited metastatic load that might perform more favorably than a distinctly disseminated disease, or even one that may be managed in a potentially curative way. Since there is currently a knowledge gap of what imaging modalities should be utilized to classify patients as having this type of tumor, we aimed to shed light on the role of conventional and marker-based imaging in the setting of synchronous oligometastatic prostate cancer as well as summarize the available evidence for its clinical application. Methods A literature search on December 15th 2017 was conducted using the Pubmed database. Results Functional imaging techniques like Ga-68 PSMA. Ga-68 PSMA PET-CT has currently been shown the best detection rates for the assessment of nodal, bone and visceral metastases, especially for smaller lesions at low PSA levels. Conclusions Functional imaging helps detect low-burden disease metastatic patients. However, these imaging modalities are not available in every center and thus clinicians may be prone to prescribe systemic treatment rather than referring patients for cytoreductive treatments. We hope that the ongoing prospective trials will help guide clinicians in making a more personalized management of synchronous metastatic patients.
Keywords
Prostate cancer, Oligometastatic, Imaging, PET-CT, PSMA, MRI, EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY, TERM ANDROGEN SUPPRESSION, RADICAL PROSTATECTOMY, PELVIC LYMPHADENECTOMY, COMPUTED-TOMOGRAPHY, BONE-SCINTIGRAPHY, LOCAL TREATMENT, METASTASES, PET/CT, RADIOTHERAPY

Downloads

  • 2018 Futterer Imaging Modalities Synchronous oligomet PC.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.36 MB

Citation

Please use this url to cite or link to this publication:

MLA
Futterer, Jurgen J., et al. “Imaging Modalities in Synchronous Oligometastatic Prostate Cancer.” WORLD JOURNAL OF UROLOGY, vol. 37, no. 12, 2019, pp. 2573–83, doi:10.1007/s00345-018-2416-2.
APA
Futterer, J. J., Surcel, C., van den Bergh, R., Borgmann, H., Briganti, A., Gandaglia, G., … Tsaur, I. (2019). Imaging modalities in synchronous oligometastatic prostate cancer. WORLD JOURNAL OF UROLOGY, 37(12), 2573–2583. https://doi.org/10.1007/s00345-018-2416-2
Chicago author-date
Futterer, Jurgen J, Cristian Surcel, Roderick van den Bergh, Hendrik Borgmann, Alberto Briganti, Giorgio Gandaglia, Alexander Kretschmer, et al. 2019. “Imaging Modalities in Synchronous Oligometastatic Prostate Cancer.” WORLD JOURNAL OF UROLOGY 37 (12): 2573–83. https://doi.org/10.1007/s00345-018-2416-2.
Chicago author-date (all authors)
Futterer, Jurgen J, Cristian Surcel, Roderick van den Bergh, Hendrik Borgmann, Alberto Briganti, Giorgio Gandaglia, Alexander Kretschmer, Piet Ost, Prasanna Sooriakumaran, Derya Tilki, Massimo Valerio, Guillaume Ploussard, Pieter De Visschere, and Igor Tsaur. 2019. “Imaging Modalities in Synchronous Oligometastatic Prostate Cancer.” WORLD JOURNAL OF UROLOGY 37 (12): 2573–2583. doi:10.1007/s00345-018-2416-2.
Vancouver
1.
Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G, et al. Imaging modalities in synchronous oligometastatic prostate cancer. WORLD JOURNAL OF UROLOGY. 2019;37(12):2573–83.
IEEE
[1]
J. J. Futterer et al., “Imaging modalities in synchronous oligometastatic prostate cancer,” WORLD JOURNAL OF UROLOGY, vol. 37, no. 12, pp. 2573–2583, 2019.
@article{8617723,
  abstract     = {Purpose Along with a number of other malignancies, the term "oligometastatic" prostate cancer has recently emerged. It represents an attempt to define a subtype of cancer with a limited metastatic load that might perform more favorably than a distinctly disseminated disease, or even one that may be managed in a potentially curative way. Since there is currently a knowledge gap of what imaging modalities should be utilized to classify patients as having this type of tumor, we aimed to shed light on the role of conventional and marker-based imaging in the setting of synchronous oligometastatic prostate cancer as well as summarize the available evidence for its clinical application.
Methods A literature search on December 15th 2017 was conducted using the Pubmed database.
Results Functional imaging techniques like Ga-68 PSMA. Ga-68 PSMA PET-CT has currently been shown the best detection rates for the assessment of nodal, bone and visceral metastases, especially for smaller lesions at low PSA levels.
Conclusions Functional imaging helps detect low-burden disease metastatic patients. However, these imaging modalities are not available in every center and thus clinicians may be prone to prescribe systemic treatment rather than referring patients for cytoreductive treatments. We hope that the ongoing prospective trials will help guide clinicians in making a more personalized management of synchronous metastatic patients.},
  author       = {Futterer, Jurgen J and Surcel, Cristian and van den Bergh, Roderick and Borgmann, Hendrik and Briganti, Alberto and Gandaglia, Giorgio and Kretschmer, Alexander and Ost, Piet and Sooriakumaran, Prasanna and Tilki, Derya and Valerio, Massimo and Ploussard, Guillaume and De Visschere, Pieter and Tsaur, Igor},
  issn         = {0724-4983},
  journal      = {WORLD JOURNAL OF UROLOGY},
  keywords     = {Prostate cancer,Oligometastatic,Imaging,PET-CT,PSMA,MRI,EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY,TERM ANDROGEN SUPPRESSION,RADICAL PROSTATECTOMY,PELVIC LYMPHADENECTOMY,COMPUTED-TOMOGRAPHY,BONE-SCINTIGRAPHY,LOCAL TREATMENT,METASTASES,PET/CT,RADIOTHERAPY},
  language     = {eng},
  number       = {12},
  pages        = {2573--2583},
  title        = {Imaging modalities in synchronous oligometastatic prostate cancer},
  url          = {http://dx.doi.org/10.1007/s00345-018-2416-2},
  volume       = {37},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: